Boston Scientific Loss Contingency Accrual increased by 2.0% to $306.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 22.4%, from $250.00M to $306.00M. Over 4 years (FY 2020 to FY 2024), Loss Contingency Accrual shows a downward trend with a -13.0% CAGR.
other_loss_contingency_accrual_at_carrying_value| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $617.00M | $548.00M | $548.00M | $509.00M | $514.00M | $304.00M | $443.00M | $416.00M | $419.00M | $407.00M | $377.00M | $283.00M | $251.00M | $250.00M | $326.00M | $316.00M | $300.00M | $306.00M |
| QoQ Change | — | -11.2% | +0.0% | -7.1% | +1.0% | -40.9% | +45.7% | -6.1% | +0.7% | -2.9% | -7.4% | -24.9% | -11.3% | -0.4% | +30.4% | -3.1% | -5.1% | +2.0% |
| YoY Change | — | — | — | — | -16.7% | -44.5% | -19.2% | -18.3% | -18.5% | +33.9% | -14.9% | -32.0% | -40.1% | -38.6% | -13.5% | +11.7% | +19.5% | +22.4% |